Lofexidine (Lucemyra) for Opioid Withdrawal | The Medical Letter, Inc.
The FDA has approved lofexidine (Lucemyra – US WorldMeds/Salix), a centrally acting alpha2 receptor agonist, to manage withdrawal symptoms in adults abruptly stopping opioid use. Available in the UK since 1992, lofexidine is the first nonopioid to be approved in the US for management of opioid withdrawal symptoms. Clonidine (Catapres, and generics), another central alpha2 receptor agonist, has been used off-label for this indication for many years.
Management of opioid withdrawal symptoms. Med Lett Drugs Ther 2018; 60 (in press).
RL Woosley and KA Romero. QT drugs list. Available at: www. crediblemeds.org. Accessed July 3, 2018.